A brand name for orforglipron, an oral (pill) GLP-1 medication from Eli Lilly approved for weight management in 2026. As a once-daily pill with fewer food-and-water timing restrictions than older oral options, it's notable for people who want to avoid injections. As a newer product, its long-term real-world track record is still thinner than the established injectables.
Related terms: Orforglipron · Semaglutide · Rybelsus